



Łódź, 18 June, 2019

**FACULTY OF BIOLOGY  
AND ENVIRONMENTAL  
PROTECTION**

University of Lodz

To whom it may concern,

Here within I declare that Mr. Damian Jacenik conducted below projects:

1. 'Estrogen receptor GPER as a modulator of inflammatory and functional diseases of the digestive system and colorectal cancer'. The project was financed by the National Centre for Science and had been granted under 'PRELUDIUM' programme (grant number: 2015/17/N/NZ5/00336). The project had been carried out in the period of: 22.02.2016 – 21.02.2019. Mr Jacenik was a project manager.
2. 'Estrogen signaling in intestinal pathophysiology'. The project has been financed by the National Centre for Science and had been granted under 'ETIUDA 5' programme (grant number: 2017/24/T/NZ5/00045). The project had been carried out in the period of: 02.10.2017 – 01.10.2018. Mr. Jacenik was a beneficiary of the doctoral scholarship.

**KIEROWNIK  
KATEDRY CYTOBIOCHEMII UŁ**

**dr hab. Anna Krześlak, profesor UŁ**

**DZIEKAN**  
Wydziału Biologii i Ochrony Środowiska  
Uniwersytetu Łódzkiego

**prof. dr hab. Andrzej Kruk**



NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

**Grant Number:** 1P20GM121176-01  
**FAIN:** P20GM121176

**Principal Investigator(s):**  
VOJO P DERETIC, PHD

**Project Title:** Autophagy, Inflammation and Metabolism (AIM) in Disease Center

Vinyard, Rena  
Director, Sponsored Projects  
MSC09 5220  
1 University of New Mexico  
Albuquerque, NM 871310001

**Award e-mailed to:** HSC-Preaward@salud.unm.edu

**Period Of Performance:**

**Budget Period:** 09/01/2017 – 08/31/2018

**Project Period:** 09/01/2017 – 08/31/2022

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$2,457,111 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number P20GM121176. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Christy S. Leake  
Grants Management Officer  
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

Additional information follows



NATIONAL CANCER INSTITUTE

**Grant Number:** 1R01CA194496-01A1  
**FAIN:** R01CA194496

**Principal Investigator(s):**  
JEFFREY B ARTERBURN, PHD  
ERIC R PROSSNITZ (contact), PHD

**Project Title:** Molecular Mechanisms and Applications of Novel ER/GPER-selective Ligands

Stacy Bigbie  
University of New Mexico  
MSC09 5220  
1 University of New Mexico  
Albuquerque, NM 871310001

**Award e-mailed to:** HSC-Preaward@salud.unm.edu

**Period Of Performance:**

**Budget Period:** 09/07/2016 – 08/31/2017

**Project Period:** 09/07/2016 – 08/31/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$320,000 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA194496. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Jason Gill  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows



NATIONAL CANCER INSTITUTE

**Grant Number:** 7R01CA207051-03  
**FAIN:** R01CA207051

**Principal Investigator(s):**  
Ellen J. Beswick, PHD

**Project Title:** G-CSF inhibition as a colorectal cancer therapy

Katelyn Dalley  
75 South 2000 East

Salt Lake City, UT 84112

**Award e-mailed to:** ospawards@osp.utah.edu

**Period Of Performance:**

**Budget Period:** 07/01/2018 – 06/30/2019

**Project Period:** 07/06/2016 – 06/30/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$348,844 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF UTAH in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA207051. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Crystal Wolfrey  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows



**Grant Number:** 2P30CA118100-11 REVISED  
**FAIN:** P30CA118100

**Principal Investigator(s):**  
CHERYL L WILLMAN, MD

**Project Title:** University of New Mexico Cancer Center Support Grant

Vinyard, Rena  
Director, Sponsored Projects  
MSC09 5220  
1 University of New Mexico  
Albuquerque, NM 871310001

**Award e-mailed to:** HSC-Preaward@salud.unm.edu

**Period Of Performance:**

**Budget Period:** 09/01/2015 – 08/31/2016

**Project Period:** 09/26/2005 – 08/31/2020

Dear Business Official:

The National Institutes of Health hereby revises this award (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA118100. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Kelly Fritz  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows



NATIONAL CANCER INSTITUTE

**Grant Number:** 2R01CA163890-06A1  
**FAIN:** R01CA163890

**Principal Investigator(s):**  
Eric R Prossnitz, PHD

**Project Title:** G protein-coupled estrogen receptor GPER and breast carcinogenesis

Stacy Bigbie  
Associate Director, Sponsored Projects Office  
MSC09 5220  
1 University of New Mexico  
Albuquerque, NM 871310001

**Award e-mailed to:** HSC-Preaward@salud.unm.edu

**Period Of Performance:**

**Budget Period:** 09/01/2018 – 08/31/2019

**Project Period:** 08/01/2012 – 08/31/2023

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$353,942 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA163890. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Amy R Bartosch  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows



**H. Keith Johnson, M.D.**  
Chairman  
**Doug Johnson, M.D.**  
Vice-Chairman  
**Ed Attrill**  
President

**Bill Wood**  
Chief Financial Officer  
**Stuart Redpath**  
Chief Operating Officer  
**Joe Swearingen**  
Assistant Treasurer

December 14, 2018

Christos Argyropoulos, MD  
Medical Director  
Dialysis Clinic, Inc.  
905 Louisiana Blvd. NE  
Albuquerque, NM 87110-7048

**RE: Reserve Funds Project #C-3937\_REVISED (248 – Albuquerque East)  
Study, "Targeting GPER to Prevent and Treat Chronic Kidney Disease"**

Dear Dr. Argyropoulos:


Your request for use of reserve funds in the amount of \$361,600.00 has been approved. This award has been revised from the previously approved award amount was \$169,500.00. This funding is to support the study, "Targeting GPER to Prevent and Treat Chronic Kidney Disease," **conducted by Eric Prossnitz**, Ph.D. at the University of New Mexico. The funding period will be October 01, 2016 – September 30, 2020.

Payments will be made according to the following schedule:

December, 2016	\$38,137.50 (paid)
April, 2017	\$38,137.50 (paid)
October, 2017	\$38,137.50 (paid)
April, 2018	\$38,137.50 (paid)
October, 2018	\$43,222.50
April, 2019	\$43,222.50
October, 2019	\$43,222.50
April, 2020	\$43,222.50
October, 2020	\$36,160.00 (\$16,950.00 + \$19,210.00; 10% w/h)

The original requirements of this award are still in effect as well as any amendments that have been executed regarding this matter.

Sincerely,

A handwritten signature in black ink that reads "Karen Majchrzak". The signature is fluid and cursive, with the first name "Karen" being more prominent than the last name "Majchrzak".

Karen Majchrzak

DCI Director of Clinical Research

cc: Doug Reinhard  
Charmain Madero  
Eric Prossnitz, Ph.D.  
Jessica Stanton  
Leslie Firkins  
Serena Cumber  
Richard Reyes